Bicycle Therapeutics (BCYC) Financials

$5.15 +0.25 (+5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$5.05 -0.10 (-1.88%)

As of 06:53 PM Eastern

Annual Income Statements for Bicycle Therapeutics

This table shows Bicycle Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-113	-181	-169
Consolidated Net Income / (Loss)	-113	-181	-169
Net Income / (Loss) Continuing Operations	-113	-181	-169
Total Pre-Tax Income	-114	-179	-174
Total Operating Income	-117	-190	-210
Total Gross Profit	14	27	35
Total Revenue	14	27	35
Operating Revenue	14	27	35
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	131	217	245
Selling, General & Admin Expense	50	60	72
Research & Development Expense	82	156	173
Total Other Income / (Expense), net	2.41	11	36
Interest Expense	3.34	3.26	2.68
Interest & Investment Income	5.76	14	34
Other Income / (Expense), net	0.00	0.00	4.48
Income Tax Expense	-1.52	1.46	-4.77
Basic Earnings per Share	($3.80)	($5.08)	($2.90)
Weighted Average Basic Shares Outstanding	29.66M	35.59M	58.21M
Diluted Earnings per Share	($3.80)	($5.08)	($2.90)
Weighted Average Diluted Shares Outstanding	29.66M	35.59M	58.21M
Weighted Average Basic & Diluted Shares Outstanding	30.02M	42.59M	69.20M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Bicycle Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-28	-30	-39	-43	-46	-53	-27	-40	-53	-50
Consolidated Net Income / (Loss)	-28	-30	-39	-43	-50	-49	-27	-40	-51	-52
Net Income / (Loss) Continuing Operations	-28	-30	-39	-43	-50	-49	-27	-40	-51	-52
Total Pre-Tax Income	-29	-30	-40	-43	-48	-49	-27	-40	-54	-53
Total Operating Income	-30	-32	-42	-43	-51	-54	-32	-47	-64	-68
Total Gross Profit	3.04	3.19	4.90	11	5.35	5.33	20	9.36	2.68	3.71
Total Revenue	3.04	3.19	4.90	11	5.35	5.33	20	9.36	2.68	3.71
Operating Revenue	3.04	3.19	4.90	11	5.35	5.33	20	9.36	2.68	3.71
Total Operating Expenses	33	35	47	55	56	60	51	56	67	71
Selling, General & Admin Expense	10	11	14	15	16	15	16	16	18	22
Research & Development Expense	23	25	32	40	40	45	35	40	48	50
Total Other Income / (Expense), net	1.17	1.79	2.12	-0.02	3.17	5.47	4.80	6.95	9.60	15
Interest Expense	0.82	0.83	0.81	0.82	0.81	0.82	0.82	0.82	0.99	0.05
Interest & Investment Income	1.99	2.64	2.93	0.81	3.99	6.28	5.62	7.77	11	10
Income Tax Expense	-0.24	-0.42	-0.62	-0.52	2.27	0.32	-0.35	0.12	-3.45	-1.08
Basic Earnings per Share	($0.96)	($1.01)	($1.30)	($1.41)	($1.26)	($1.11)	($0.62)	($0.77)	($0.74)	($0.77)
Weighted Average Basic Shares Outstanding	29.68M	29.66M	30.00M	30.19M	39.58M	35.59M	42.56M	51.99M	68.99M	58.21M
Diluted Earnings per Share	($0.96)	($1.01)	($1.30)	($1.41)	($1.26)	($1.11)	($0.62)	($0.77)	($0.74)	($0.77)
Weighted Average Diluted Shares Outstanding	29.68M	29.66M	30.00M	30.19M	39.58M	35.59M	42.56M	51.99M	68.99M	58.21M
Weighted Average Basic & Diluted Shares Outstanding	29.69M	30.02M	30.04M	41.42M	42.42M	42.59M	42.78M	68.99M	69.05M	69.20M

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-100	188	353
Net Cash From Operating Activities	-86	-61	-165
Net Cash From Continuing Operating Activities	-86	-61	-165
Net Income / (Loss) Continuing Operations	-113	-181	-169
Consolidated Net Income / (Loss)	-113	-181	-169
Depreciation Expense	3.69	6.55	7.17
Non-Cash Adjustments To Reconcile Net Income	20	34	28
Changes in Operating Assets and Liabilities, net	2.71	79	-31
Net Cash From Investing Activities	-19	-2.93	-1.24
Net Cash From Continuing Investing Activities	-19	-2.93	-1.24
Purchase of Property, Plant & Equipment	-19	-2.93	-1.24
Net Cash From Financing Activities	6.69	250	520
Net Cash From Continuing Financing Activities	6.69	250	520
Repayment of Debt	0.00	0.00	-32
Issuance of Common Equity	5.70	249	544
Other Financing Activities, net	0.99	0.68	7.53
Effect of Exchange Rate Changes	-1.12	1.35	-0.69
Cash Interest Paid	2.79	2.75	1.40
Cash Income Taxes Paid	2.23	0.56	0.79

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-11	-22	-45	47	232	-46	-69	504	-71	-11
Net Cash From Operating Activities	-5.87	-30	-46	34	-1.03	-47	-71	-45	-40	-9.40
Net Cash From Continuing Operating Activities	-5.87	-30	-46	34	-1.03	-47	-71	-45	-40	-9.40
Net Income / (Loss) Continuing Operations	-28	-30	-39	-43	-50	-49	-27	-40	-51	-52
Consolidated Net Income / (Loss)	-28	-30	-39	-43	-50	-49	-27	-40	-51	-52
Depreciation Expense	1.26	1.39	1.56	1.65	1.69	1.65	1.66	1.64	2.17	1.70
Non-Cash Adjustments To Reconcile Net Income	7.90	1.68	1.22	25	3.58	3.76	-5.56	3.93	3.80	26
Changes in Operating Assets and Liabilities, net	13	-3.40	-10	50	44	-3.60	-40	-10	5.00	15
Net Cash From Investing Activities	-2.98	-1.45	-2.10	-0.28	-0.50	-0.05	-0.01	-0.42	-0.44	-0.37
Net Cash From Continuing Investing Activities	-2.98	-1.45	-2.10	-0.28	-0.50	-0.05	-0.01	-0.42	-0.44	-0.37
Purchase of Property, Plant & Equipment	-2.98	-1.45	-2.10	-0.28	-0.50	-0.05	-0.01	-0.42	-0.44	-0.37
Net Cash From Financing Activities	0.16	5.89	2.72	12	235	0.39	1.87	550	-32	0.20
Net Cash From Continuing Financing Activities	0.16	5.89	2.72	12	235	0.39	1.87	550	-32	0.20
Repayment of Debt	-	-	-	-	-	-	-	-	-	-0.04
Other Financing Activities, net	0.16	0.19	0.00	0.17	0.14	0.38	1.87	4.50	0.91	0.25
Effect of Exchange Rate Changes	-2.60	3.55	0.45	0.51	-0.90	1.29	-0.42	-0.19	1.70	-1.78
Cash Interest Paid	0.71	0.69	0.68	0.69	0.69	0.69	0.69	0.46	0.23	0.02

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	411	595	957
Total Current Assets	369	562	929
Cash & Equivalents	339	526	880
Prepaid Expenses	9.02	11	13
Other Current Assets	19	24	36
Plant, Property, & Equipment, net	19	15	9.52
Total Noncurrent Assets	22	19	19
Other Noncurrent Operating Assets	22	19	19
Total Liabilities & Shareholders' Equity	411	595	957
Total Liabilities	140	224	164
Total Current Liabilities	53	70	67
Accounts Payable	6.47	13	16
Accrued Expenses	26	32	41
Current Deferred Revenue	20	25	10
Total Noncurrent Liabilities	86	155	97
Long-Term Debt	30	31	0.00
Noncurrent Deferred Revenue	41	110	91
Other Noncurrent Operating Liabilities	15	14	5.11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	271	371	793
Total Preferred & Common Equity	271	371	793
Total Common Equity	271	371	793
Common Stock	601	884	1,474
Retained Earnings	-331	-512	-681
Accumulated Other Comprehensive Income / (Loss)	0.39	-1.30	0.12

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	417	429	454	639	547	1,057	997
Total Current Assets	381	381	408	603	516	1,028	966
Cash & Equivalents	361	294	340	572	457	961	891
Prepaid Expenses	8.45	11	10	14	20	20	17
Other Current Assets	11	27	13	17	39	46	58
Plant, Property, & Equipment, net	16	18	18	16	13	12	12
Total Noncurrent Assets	20	29	28	20	18	18	19
Other Noncurrent Operating Assets	20	29	28	20	18	18	19
Total Liabilities & Shareholders' Equity	417	429	454	639	547	1,057	997
Total Liabilities	128	186	234	223	191	184	166
Total Current Liabilities	42	53	72	70	50	70	56
Accounts Payable	7.06	2.81	5.25	8.49	7.06	7.45	5.71
Accrued Expenses	18	25	37	34	26	28	39
Current Deferred Revenue	16	25	30	27	16	12	11
Total Noncurrent Liabilities	86	133	162	153	142	114	109
Long-Term Debt	30	30	31	31	31	8.51	0.00
Noncurrent Deferred Revenue	42	84	115	108	98	94	98
Other Noncurrent Operating Liabilities	14	18	16	15	13	11	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	289	243	220	416	356	874	831
Total Preferred & Common Equity	289	243	220	416	356	874	831
Total Common Equity	289	243	220	416	356	874	831
Common Stock	590	613	634	876	895	1,453	1,463
Retained Earnings	-301	-370	-413	-463	-538	-578	-629
Accumulated Other Comprehensive Income / (Loss)	0.53	0.07	-0.88	2.89	-0.78	-1.09	-3.19

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	23.65%	86.52%	30.76%
EBITDA Growth	-75.93%	-62.35%	-8.08%
EBIT Growth	-77.78%	-62.83%	-8.13%
NOPAT Growth	-77.78%	-62.83%	-10.49%
Net Income Growth	-68.69%	-60.28%	6.44%
EPS Growth	-42.32%	-33.68%	42.91%
Operating Cash Flow Growth	-482.07%	29.59%	-171.70%
Free Cash Flow Firm Growth	-1,028.75%	56.45%	-300.74%
Invested Capital Growth	39.16%	-227.92%	30.72%
Revenue Q/Q Growth	-3.89%	8.64%	-4.40%
EBITDA Q/Q Growth	-13.24%	-13.46%	-4.70%
EBIT Q/Q Growth	-13.85%	-13.12%	-4.56%
NOPAT Q/Q Growth	-13.85%	-13.12%	-6.84%
Net Income Q/Q Growth	-11.85%	-11.84%	-1.66%
EPS Q/Q Growth	-11.76%	-2.01%	10.49%
Operating Cash Flow Q/Q Growth	-30.00%	-38.90%	18.70%
Free Cash Flow Firm Q/Q Growth	-19.39%	-36.57%	8.81%
Invested Capital Q/Q Growth	8.88%	0.53%	-44.51%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-781.06%	-679.86%	-561.93%
Operating Margin	-806.56%	-704.13%	-594.96%
EBIT Margin	-806.56%	-704.13%	-582.27%
Profit (Net Income) Margin	-779.35%	-669.72%	-479.18%
Tax Burden Percent	98.67%	100.81%	97.26%
Interest Burden Percent	97.93%	94.35%	84.62%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-36.53%	-56.31%	-29.04%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-26.20%	-37.76%	-26.46%
Return on Assets (ROA)	-25.32%	-35.92%	-21.78%
Return on Common Equity (ROCE)	-36.53%	-56.31%	-29.04%
Return on Equity Simple (ROE_SIMPLE)	-41.63%	-48.71%	-21.31%
Net Operating Profit after Tax (NOPAT)	-82	-133	-147
NOPAT Margin	-564.59%	-492.89%	-416.47%
Net Nonoperating Expense Percent (NNEP)	-8.66%	-11.86%	-3.22%
Return On Investment Capital (ROIC_SIMPLE)	-27.12%	-33.11%	-18.52%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	342.30%	224.00%	204.62%
R&D to Revenue	564.26%	580.13%	490.34%
Operating Expenses to Revenue	906.56%	804.13%	694.96%
Earnings before Interest and Taxes (EBIT)	-117	-190	-205
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-113	-183	-198
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.25	2.07	1.22
Price to Tangible Book Value (P/TBV)	3.25	2.07	1.22
Price to Revenue (P/Rev)	60.76	28.43	27.40
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	39.41	10.06	2.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.11	0.08	0.00
Long-Term Debt to Equity	0.11	0.08	0.00
Financial Leverage	-1.16	-1.25	-1.18
Leverage Ratio	1.44	1.57	1.33
Compound Leverage Factor	1.41	1.48	1.13
Debt to Total Capital	10.07%	7.64%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	10.07%	7.64%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.93%	92.36%	100.00%
Debt to EBITDA	-0.27	-0.17	0.00
Net Debt to EBITDA	2.73	2.70	0.00
Long-Term Debt to EBITDA	-0.27	-0.17	0.00
Debt to NOPAT	-0.37	-0.23	0.00
Net Debt to NOPAT	3.78	3.73	0.00
Long-Term Debt to NOPAT	-0.37	-0.23	0.00
Altman Z-Score	2.66	0.83	2.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	6.92	8.08	13.81
Quick Ratio	6.40	7.57	13.08
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-106	-46	-185
Operating Cash Flow to CapEx	-453.53%	-2,069.92%	-13,337.98%
Free Cash Flow to Firm to Interest Expense	-31.74	-14.17	-69.02
Operating Cash Flow to Interest Expense	-25.75	-18.58	-61.37
Operating Cash Flow Less CapEx to Interest Expense	-31.43	-19.48	-61.83
Efficiency Ratios	-	-	-
Asset Turnover	0.03	0.05	0.05
Accounts Receivable Turnover	9.50	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.30	1.60	2.94
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	38.42	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	38.42	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-38	-125	-86
Invested Capital Turnover	-0.29	-0.33	-0.33
Increase / (Decrease) in Invested Capital	24	-87	38
Enterprise Value (EV)	570	271	87
Market Capitalization	879	767	967
Book Value per Share	$9.12	$8.74	$11.49
Tangible Book Value per Share	$9.12	$8.74	$11.49
Total Capital	301	402	793
Total Debt	30	31	0.00
Total Long-Term Debt	30	31	0.00
Net Debt	-309	-496	-880
Capital Expenditures (CapEx)	19	2.93	1.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-34	-18
Debt-free Net Working Capital (DFNWC)	316	492	861
Net Working Capital (NWC)	316	492	861
Net Nonoperating Expense (NNE)	31	48	22
Net Nonoperating Obligations (NNO)	-309	-496	-880
Total Depreciation and Amortization (D&A)	3.69	6.55	7.17
Debt-free, Cash-free Net Working Capital to Revenue	-159.81%	-126.38%	-51.44%
Debt-free Net Working Capital to Revenue	2,185.17%	1,825.07%	2,441.89%
Net Working Capital to Revenue	2,185.17%	1,825.07%	2,441.89%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.80)	($5.08)	($2.90)
Adjusted Weighted Average Basic Shares Outstanding	29.66M	35.59M	58.21M
Adjusted Diluted Earnings per Share	($3.80)	($5.08)	($2.90)
Adjusted Weighted Average Diluted Shares Outstanding	29.66M	35.59M	58.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.02M	42.59M	69.20M
Normalized Net Operating Profit after Tax (NOPAT)	-82	-133	-147
Normalized NOPAT Margin	-564.59%	-492.89%	-416.47%
Pre Tax Income Margin	-789.88%	-664.32%	-492.69%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-34.88	-58.21	-76.53
NOPAT to Interest Expense	-24.42	-40.75	-54.74
EBIT Less CapEx to Interest Expense	-40.56	-59.11	-76.99
NOPAT Less CapEx to Interest Expense	-30.10	-41.65	-55.20
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-29.84%	-15.54%	26.84%	160.32%	76.05%	67.38%	298.90%	-17.86%	-50.00%	-30.44%
EBITDA Growth	-104.16%	-74.98%	-49.27%	-55.58%	-72.34%	-70.58%	25.31%	-8.52%	-25.59%	-25.44%
EBIT Growth	-108.19%	-78.72%	-52.66%	-58.09%	-70.69%	-68.37%	24.13%	-8.18%	-25.69%	-24.76%
NOPAT Growth	-108.19%	-78.72%	-52.66%	-57.92%	-70.69%	-68.37%	24.13%	-8.20%	-25.69%	-24.76%
Net Income Growth	-93.13%	-66.20%	-41.72%	-58.80%	-76.03%	-63.78%	32.00%	6.55%	-1.81%	-5.61%
EPS Growth	-62.71%	-65.57%	-39.78%	-56.67%	-31.25%	-9.90%	52.31%	45.39%	41.27%	30.63%
Operating Cash Flow Growth	-127.03%	-190.46%	-75.80%	244.90%	82.54%	-56.02%	-52.70%	-230.89%	-3,786.05%	80.13%
Free Cash Flow Firm Growth	-264.73%	-296.74%	-1,648.51%	290.21%	226.63%	203.67%	149.37%	-331.71%	-329.17%	-275.71%
Invested Capital Growth	29.15%	39.16%	57.04%	-187.59%	-200.41%	-227.92%	-246.66%	36.94%	52.31%	30.72%
Revenue Q/Q Growth	-30.56%	4.77%	53.72%	132.78%	-53.04%	-0.39%	266.35%	-52.07%	-71.41%	38.57%
EBITDA Q/Q Growth	-6.89%	-8.18%	-30.56%	-3.05%	-18.40%	-7.07%	42.83%	-49.73%	-37.03%	-6.95%
EBIT Q/Q Growth	-9.11%	-8.24%	-29.78%	-3.15%	-17.80%	-6.77%	41.52%	-47.08%	-36.87%	-5.98%
NOPAT Q/Q Growth	-9.01%	-8.24%	-29.78%	-3.13%	-17.83%	-6.77%	41.52%	-47.08%	-36.87%	-5.98%
Net Income Q/Q Growth	-5.66%	-5.75%	-30.31%	-9.06%	-17.12%	1.60%	45.90%	-49.88%	-27.60%	-2.07%
EPS Q/Q Growth	-6.67%	-5.21%	-28.71%	-8.46%	10.64%	11.90%	44.14%	-24.19%	3.90%	-4.05%
Operating Cash Flow Q/Q Growth	75.05%	-416.25%	-53.13%	173.47%	-103.01%	-4,513.46%	-49.87%	37.03%	10.74%	76.41%
Free Cash Flow Firm Q/Q Growth	-154.51%	-23.75%	-19.32%	150.62%	69.43%	1.32%	-43.18%	-337.57%	-67.58%	22.32%
Invested Capital Q/Q Growth	-33.71%	8.88%	46.83%	-343.90%	-39.67%	0.53%	43.79%	19.25%	-5.63%	-44.51%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-937.34%	-967.82%	-822.02%	-363.91%	-917.54%	-986.33%	-153.91%	-480.79%	-2,304.71%	-1,778.83%
Operating Margin	-978.91%	-1,011.33%	-853.82%	-378.27%	-949.12%	-1,017.35%	-162.40%	-498.31%	-2,385.87%	-1,824.78%
EBIT Margin	-978.91%	-1,011.33%	-853.82%	-378.35%	-949.12%	-1,017.35%	-162.40%	-498.31%	-2,385.87%	-1,824.78%
Profit (Net Income) Margin	-932.47%	-941.22%	-797.88%	-373.81%	-932.32%	-921.01%	-136.01%	-425.30%	-1,898.43%	-1,398.44%
Tax Burden Percent	99.17%	98.62%	98.44%	98.80%	104.77%	100.66%	98.70%	100.29%	93.64%	97.96%
Interest Burden Percent	96.06%	94.37%	94.93%	100.00%	93.76%	89.94%	84.86%	85.10%	84.97%	78.23%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-43.79%	-36.53%	-43.32%	-52.68%	-45.80%	-56.31%	-56.13%	-30.24%	-26.67%	-29.04%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-42.18%	-32.85%	-29.79%	-18.94%	-44.64%	-54.56%	-13.85%	-26.09%	-107.66%	-82.94%
Return on Assets (ROA)	-40.18%	-30.58%	-27.84%	-18.71%	-43.85%	-49.40%	-11.60%	-22.27%	-85.66%	-63.56%
Return on Common Equity (ROCE)	-43.79%	-36.53%	-43.32%	-52.68%	-45.80%	-56.31%	-56.13%	-30.24%	-26.67%	-29.04%
Return on Equity Simple (ROE_SIMPLE)	-34.81%	0.00%	-51.08%	-63.60%	-38.83%	0.00%	-47.23%	-18.93%	-20.01%	0.00%
Net Operating Profit after Tax (NOPAT)	-21	-23	-29	-30	-36	-38	-22	-33	-45	-47
NOPAT Margin	-685.24%	-707.93%	-597.67%	-264.79%	-664.39%	-712.15%	-113.68%	-348.82%	-1,670.11%	-1,277.35%
Net Nonoperating Expense Percent (NNEP)	-2.68%	-2.07%	-3.06%	-3.81%	-3.29%	-2.77%	-1.27%	-1.15%	-0.85%	-0.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.49%	-	-	-	-9.45%	-	-	-	-5.97%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	330.49%	335.23%	295.92%	129.75%	304.20%	278.92%	83.88%	170.38%	682.25%	582.34%
R&D to Revenue	748.42%	776.11%	657.90%	348.51%	744.92%	838.44%	178.52%	427.94%	1,803.62%	1,342.45%
Operating Expenses to Revenue	1,078.91%	1,111.33%	953.82%	478.27%	1,049.12%	1,117.35%	262.40%	598.31%	2,485.87%	1,924.78%
Earnings before Interest and Taxes (EBIT)	-30	-32	-42	-43	-51	-54	-32	-47	-64	-68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-28	-31	-40	-41	-49	-53	-30	-45	-62	-66
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.38	3.25	2.63	3.48	2.00	2.07	2.97	0.99	1.88	1.22
Price to Tangible Book Value (P/TBV)	2.38	3.25	2.63	3.48	2.00	2.07	2.97	0.99	1.88	1.22
Price to Revenue (P/Rev)	45.87	60.76	41.20	34.05	33.51	28.43	25.39	21.88	42.31	27.40
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.86	39.41	24.20	20.29	11.71	10.06	15.14	0.00	18.17	2.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.11	0.13	0.14	0.07	0.08	0.09	0.04	0.00	0.00
Long-Term Debt to Equity	0.10	0.11	0.13	0.14	0.07	0.08	0.09	0.01	0.00	0.00
Financial Leverage	-1.22	-1.16	-1.12	-1.23	-1.24	-1.25	-1.15	-1.13	-1.15	-1.18
Leverage Ratio	1.52	1.44	1.55	1.69	1.50	1.57	1.63	1.38	1.31	1.33
Compound Leverage Factor	1.46	1.36	1.47	1.69	1.40	1.41	1.38	1.18	1.11	1.04
Debt to Total Capital	9.46%	10.07%	11.12%	12.18%	6.85%	7.64%	7.96%	3.42%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.48%	0.00%	0.00%
Long-Term Debt to Total Capital	9.46%	10.07%	11.12%	12.18%	6.85%	7.64%	7.96%	0.94%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.54%	89.93%	88.88%	87.82%	93.15%	92.36%	92.04%	96.58%	100.00%	100.00%
Debt to EBITDA	-0.30	-0.27	-0.24	-0.22	-0.19	-0.17	-0.18	-0.17	0.00	0.00
Net Debt to EBITDA	3.32	2.73	2.09	2.20	3.35	2.70	2.46	5.26	0.00	0.00
Long-Term Debt to EBITDA	-0.30	-0.27	-0.24	-0.22	-0.19	-0.17	-0.18	-0.05	0.00	0.00
Debt to NOPAT	-0.42	-0.37	-0.33	-0.30	-0.26	-0.23	-0.24	-0.24	0.00	0.00
Net Debt to NOPAT	4.62	3.78	2.87	3.01	4.61	3.73	3.39	7.25	0.00	0.00
Long-Term Debt to NOPAT	-0.42	-0.37	-0.33	-0.30	-0.26	-0.23	-0.24	-0.07	0.00	0.00
Altman Z-Score	3.01	3.34	1.49	1.32	2.01	1.58	2.85	3.04	5.69	3.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.18	6.92	7.19	5.65	8.65	8.08	10.42	14.77	17.13	13.81
Quick Ratio	8.70	6.40	6.49	5.33	8.20	7.57	9.23	13.81	15.79	13.08
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-47	-56	28	48	49	28	-66	-110	-86
Operating Cash Flow to CapEx	-196.75%	-2,093.16%	-2,211.10%	12,309.03%	-204.18%	-92,721.57%	-590,575.00%	-10,625.48%	-9,156.78%	-2,553.26%
Free Cash Flow to Firm to Interest Expense	-46.53	-56.95	-69.47	34.61	59.14	59.48	33.75	-79.90	-111.78	-1,648.02
Operating Cash Flow to Interest Expense	-7.19	-36.69	-57.44	41.53	-1.26	-57.67	-86.32	-54.16	-40.36	-180.69
Operating Cash Flow Less CapEx to Interest Expense	-10.84	-38.45	-60.04	41.19	-1.88	-57.73	-86.34	-54.67	-40.80	-187.77
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.03	0.03	0.05	0.05	0.05	0.09	0.05	0.05	0.05
Accounts Receivable Turnover	0.00	9.50	0.00	0.82	0.00	0.00	0.00	1.75	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.61	1.30	1.14	1.31	1.56	1.60	2.68	2.71	2.72	2.94
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	38.42	0.00	446.48	0.00	0.00	0.00	209.01	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	38.42	0.00	446.48	0.00	0.00	0.00	209.01	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-42	-38	-20	-90	-125	-125	-70	-57	-60	-86
Invested Capital Turnover	-0.30	-0.29	-0.46	-0.37	-0.30	-0.33	-0.92	-0.54	-0.40	-0.33
Increase / (Decrease) in Invested Capital	17	24	27	-59	-84	-87	-50	33	66	38
Enterprise Value (EV)	359	570	375	457	291	271	630	-65	670	87
Market Capitalization	690	879	639	767	832	767	1,056	866	1,561	967
Book Value per Share	$9.75	$9.12	$8.10	$7.33	$10.04	$8.74	$8.37	$20.43	$12.05	$11.49
Tangible Book Value per Share	$9.75	$9.12	$8.10	$7.33	$10.04	$8.74	$8.37	$20.43	$12.05	$11.49
Total Capital	320	301	274	251	447	402	387	905	831	793
Total Debt	30	30	30	31	31	31	31	31	0.00	0.00
Total Long-Term Debt	30	30	30	31	31	31	31	8.51	0.00	0.00
Net Debt	-331	-309	-263	-310	-541	-496	-426	-930	-891	-880
Capital Expenditures (CapEx)	2.98	1.45	2.10	0.28	0.50	0.05	0.01	0.42	0.44	0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-23	34	-4.27	-39	-34	9.46	20	19	-18
Debt-free Net Working Capital (DFNWC)	340	316	328	336	533	492	466	981	910	861
Net Working Capital (NWC)	340	316	328	336	533	492	466	959	910	861
Net Nonoperating Expense (NNE)	7.52	7.43	9.80	12	14	11	4.36	7.16	6.11	4.49
Net Nonoperating Obligations (NNO)	-331	-309	-263	-310	-541	-496	-426	-930	-891	-880
Total Depreciation and Amortization (D&A)	1.26	1.39	1.56	1.65	1.69	1.65	1.66	1.64	2.17	1.70
Debt-free, Cash-free Net Working Capital to Revenue	-144.43%	-159.81%	222.23%	-18.96%	-156.21%	-126.38%	22.72%	49.74%	51.30%	-51.44%
Debt-free Net Working Capital to Revenue	2,257.51%	2,185.17%	2,117.93%	1,492.87%	2,147.81%	1,825.07%	1,121.01%	2,479.02%	2,465.69%	2,441.89%
Net Working Capital to Revenue	2,257.51%	2,185.17%	2,117.93%	1,492.87%	2,147.81%	1,825.07%	1,121.01%	2,422.41%	2,465.69%	2,441.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.96)	($1.01)	($1.30)	($1.41)	($1.26)	($1.11)	($0.62)	($0.77)	($0.74)	($0.77)
Adjusted Weighted Average Basic Shares Outstanding	29.68M	29.66M	30.00M	30.19M	39.58M	35.59M	42.56M	51.99M	68.99M	58.21M
Adjusted Diluted Earnings per Share	($0.96)	($1.01)	($1.30)	($1.41)	($1.26)	($1.11)	($0.62)	($0.77)	($0.74)	($0.77)
Adjusted Weighted Average Diluted Shares Outstanding	29.68M	29.66M	30.00M	30.19M	39.58M	35.59M	42.56M	51.99M	68.99M	58.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.69M	30.02M	30.04M	41.42M	42.42M	42.59M	42.78M	68.99M	69.05M	69.20M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-23	-29	-30	-36	-38	-22	-33	-45	-47
Normalized NOPAT Margin	-685.24%	-707.93%	-597.67%	-264.79%	-664.39%	-712.15%	-113.68%	-348.82%	-1,670.11%	-1,277.35%
Pre Tax Income Margin	-940.30%	-954.41%	-810.50%	-378.35%	-889.87%	-915.01%	-137.80%	-424.07%	-2,027.28%	-1,427.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-36.42	-39.00	-51.74	-52.52	-62.40	-66.14	-38.63	-56.61	-64.69	-1,301.21
NOPAT to Interest Expense	-25.50	-27.30	-36.22	-36.76	-43.68	-46.30	-27.04	-39.63	-45.28	-910.85
EBIT Less CapEx to Interest Expense	-40.08	-40.75	-54.33	-52.86	-63.02	-66.20	-38.65	-57.12	-65.13	-1,308.29
NOPAT Less CapEx to Interest Expense	-29.15	-29.05	-38.81	-37.09	-44.30	-46.36	-27.06	-40.14	-45.72	-917.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Bicycle Therapeutics (BCYC) has driven notable liquidity from financing activity in 2024, while continuing to invest in its pipeline. Across the last four quarters, the company shows strong cash on hand thanks to equity raises, but persistent net losses and high operating spend remain as key considerations for investors. Below is a concise trend summary drawn from the quarterly income statements, cash flow statements, and balance sheets provided for 2022–2024.

Major equity financing in Q2 2024: Issuance of Common Equity totaled about $545.1 million, and net cash from financing activities was roughly $549.6 million, substantially boosting liquidity.
Very strong cash runway in mid-2024: Cash and cash equivalents were about $961.4 million in Q2 2024, signaling substantial liquidity to fund ongoing R&D and operations.
No debt burden: Long-term debt is reported as zero across the observed periods, preserving financial flexibility and easing near-term financing constraints.
Continued financing support into Q4 2024: Net cash from financing activities in Q4 2024 remained positive (roughly $0.2–$0.4 million range), helping to preserve liquidity without new debt obligations.
Revenue shows quarterly volatility, not a steady growth trend: Operating revenue moved from about $19.5M (Q1 2024) down to $9.36M (Q2 2024), then to $2.68M (Q3 2024) and $3.71M (Q4 2024), indicating inconsistent quarterly growth.
Ongoing, high R&D and SG&A outlays: R&D expenses remained high (e.g., roughly $34.9M in Q1 2024 up to ~$49.8M in Q4 2024) and SG&A stayed elevated, reflecting persistent pipeline investment rather than immediate margin relief.
Some quarters show zero cost of revenue: In certain quarters, total cost of revenue is reported as zero, which can affect margin interpretation and may reflect timing of revenue recognition or non-cash elements; this is not a consistent margin signal.
Persistent net losses: Net income attributable to common shareholders was negative in every quarter shown, with Q4 2024 at about -$51.8 million and Q3 2024 around -$52.9 million (restated numbers consistent with quarterly reporting).
Operating cash flow remains negative: Cash from operating activities was negative in each quarter, signaling ongoing cash burn before financing activities (e.g., -$9–$70+ million in various quarters, depending on the period).
Per-share metrics reflect ongoing losses: Basic and diluted earnings per share were negative across the quarters (e.g., -$0.77 in several quarters), indicating no near-term profitability for common shareholders.

05/06/26 07:52 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bicycle Therapeutics' Financials

When does Bicycle Therapeutics' financial year end?

According to the most recent income statement we have on file, Bicycle Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bicycle Therapeutics' net income changed over the last 2 years?

Bicycle Therapeutics' net income appears to be on an upward trend, with a most recent value of -$169.03 million in 2024, rising from -$112.72 million in 2022. The previous period was -$180.66 million in 2023. See where experts think Bicycle Therapeutics is headed by visiting Bicycle Therapeutics' forecast page.

What is Bicycle Therapeutics' operating income?

Bicycle Therapeutics' total operating income in 2024 was -$209.87 million, based on the following breakdown:

Total Gross Profit: $35.28 million
Total Operating Expenses: $245.15 million

How has Bicycle Therapeutics' revenue changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' total revenue changed from $14.46 million in 2022 to $35.28 million in 2024, a change of 143.9%.

How much debt does Bicycle Therapeutics have?

Bicycle Therapeutics' total liabilities were at $163.81 million at the end of 2024, a 27.0% decrease from 2023, and a 17.2% increase since 2022.

How much cash does Bicycle Therapeutics have?

In the past 2 years, Bicycle Therapeutics' cash and equivalents has ranged from $339.15 million in 2022 to $879.52 million in 2024, and is currently $879.52 million as of their latest financial filing in 2024.

How has Bicycle Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' book value per share changed from 9.12 in 2022 to 11.49 in 2024, a change of 25.9%.

Related Companies

Financial statements for NASDAQ:BCYC last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Bicycle Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Financials

Annual Income Statements for Bicycle Therapeutics

Quarterly Income Statements for Bicycle Therapeutics

Annual Cash Flow Statements for Bicycle Therapeutics

Quarterly Cash Flow Statements for Bicycle Therapeutics

Annual Balance Sheets for Bicycle Therapeutics

Quarterly Balance Sheets for Bicycle Therapeutics

Annual Metrics And Ratios for Bicycle Therapeutics

Quarterly Metrics And Ratios for Bicycle Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Bicycle Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools